Science & Enterprise subscription

Follow us on Twitter

  • Spark Therapeutics, a developer of gene therapies, is gaining access to a technology that programs DNA sequences li… https://t.co/WGboSsrf7U
    about 15 hours ago
  • New post on Science and Enterprise: Gene Therapy Company Exploring DNA Circuit Technology https://t.co/2YUM4DVZRK #Science #Business
    about 15 hours ago
  • A study with lab mice shows an experimental vaccine with engineered bacteria produces antibodies and protects again… https://t.co/3JtSqD1Sa2
    about 19 hours ago
  • New post on Science and Enterprise: Vaccine Stops Lyme Bacteria in Preclinical Test https://t.co/7H0Lc90nRe #Science #Business
    about 19 hours ago
  • Stop the panic porn ... Coronavirus Variants Don’t Have to Be Scary. Still, Mask Up. https://t.co/d6aDu2Ucj6
    about 22 hours ago

Please share Science & Enterprise

Trial to Test Direct Crispr Blood Stem Cell Edits

Sickle cells illustration

A clinical trial is set to begin that tests a direct form of gene editing with Crispr to correct inherited malfunctioning genes causing sickle cell disease. . . . → Read More: Trial to Test Direct Crispr Blood Stem Cell Edits

Cell-Based Fish Company Gains $8.25M in Seed Funds

Bluu Bioscience founders

The start-up enterprise Bluu Biosciences is underway creating seafood products from fish stem cells, and raising $US 8.25 million in seed funds. . . . → Read More: Cell-Based Fish Company Gains $8.25M in Seed Funds

Biotech Manufacturer Gains $525M in New Funds

BaseCamp lab

A company providing specialized lab and manufacturing services for cell and gene therapy developers is raising $525 million in its third venture funding round. . . . → Read More: Biotech Manufacturer Gains $525M in New Funds

In-Body Gene Editing Tested as Sickle Cell Treatment

Crispr graphic

Tests with lab mice show the feasibility of editing genes in blood-forming stem cells in bone marrow as a potential treatment for sickle cell disease. . . . → Read More: In-Body Gene Editing Tested as Sickle Cell Treatment

ALS Trial Results Deemed Insufficient for FDA Approval

Neurons illustration

An ALS treatment developer says the Food and Drug Administration advised the company’s clinical trial data would likely not support approval for patient use. . . . → Read More: ALS Trial Results Deemed Insufficient for FDA Approval

Engineered Cell Therapy Company Issues $588M IPO

NASDAQ share price display

A company developing regenerative therapies with engineered stem cells for cancer and other diseases is raising $587.5 million in its initial public offering or IPO. . . . → Read More: Engineered Cell Therapy Company Issues $588M IPO

Biotech Licenses mRNA Technology for Aging

Hands of older person

A biotechnology enterprise is licensing research from Stanford University on messenger RNA to produce proteins that rejuvenate cells damaged by aging. . . . → Read More: Biotech Licenses mRNA Technology for Aging

Stem Cells Help Severe Covid-19 Cases Recover

lung illustration

Results of a clinical trial show stem cells from umbilical cord linings help patients with severe respiratory disease recover and survive from Covid-19 infections. . . . → Read More: Stem Cells Help Severe Covid-19 Cases Recover

Trial OKed for Rare Disease Gene Therapy

Nerve cells illustration

A start-up biotech company says it received clearance from the Food and Drug Administration to begin a clinical trial of its gene therapy for Krabbe disease. . . . → Read More: Trial OKed for Rare Disease Gene Therapy

ALS Stem Cell Treatments Found Safe, Slow Progression

Man in wheelchair

Results from an early clinical trial of stem cells to treat amyotrophic lateral sclerosis, or ALS, shows the therapy is safe and slows progression of the disease. . . . → Read More: ALS Stem Cell Treatments Found Safe, Slow Progression